Please note: A previous version of this advisory incorrectly stated that MARAC is aware of three cases of leukemia and other cancer-like conditions in patients who have undergone gene therapy. MARAC is only aware of two such cases. The below statement has been updated accordingly.

May 15, 2021 - The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee is aware of two cases of leukemia or other cancer-like conditions in people who have undergone gene therapy for sickle cell disease. This is more than would be expected given the small number of individuals who have undergone gene therapy to date. It is unclear why cancer developed in these individuals. The mission of SCDAA is to promote the best interests of individuals living with SCD. Accordingly, SCDAA MARAC urges action in three directions:

1. Informing patients, families and others about the current understanding of cancer risk as it pertains to sickle cell disease in a clear and accurate way.
   1. Educate individuals with SCD who are participating in gene therapy (gene editing as well as lentiviral gene transfer) and other stem cell transplants (bone marrow therapies). Ensure that the consent forms reflect the recent findings and potential risks of leukemia and MDS.
   2. Educate the greater SCD community by providing cancer risk estimates in the general population of individuals with SCD treated with other types of therapies.
   3. Enlist experts in cancer genetic risk communication (e.g., NCI) and SCD stakeholders to develop education about risks of cancer in SCD.

2. Funding for research to better understand and address cancer-related risks of gene therapy and stem cell transplant (bone marrow therapies) in sickle cell disease.
   1. Understand whether sickle cell disease intrinsically involves an increased risk of cancer; and, if so, what causes the increased risk.
   2. Identify people living with sickle cell disease who are at increased risk for the development of cancer as they undergo “bone marrow therapies.”
   3. Identify components of “bone marrow therapies” that increase risk of cancer.
   4. Bring together scientific experts from the fields of SCD, cancer, stem cell transplant and gene therapy to answer these questions.

3. Funding for and creation of a way to collect information about cancer-related risks from all studies that involve “bone marrow therapies” for sickle cell disease globally.
SCDAA Medical and Research Advisory Committee Members

Miguel R. Abboud, MD
Professor of Pediatrics and Pediatric Hematology-Oncology
Chairman
Department of Pediatrics and Adolescent Medicine
American University of Beirut, Lebanon

Deepika Darbari, MD
Center for Cancer and Blood Disorders
Children’s National Health System
Professor of Pediatrics
George Washington University School of Medicine and Health Sciences
Washington, DC

Biree Andemariam, MD
Vice Chair, Sickle Cell Disease Association of America
Director, New England Sickle Cell Institute
Associate Professor of Medicine
University of Connecticut Health
Farmington, Connecticut

Payal Desai, MD
Associate Professor
Director of Sickle Cell Research
The Ohio State University
JamesCare at Ohio State East Hospital
Columbus, Ohio

Shawn Bediako, PhD
Professor
Department of Psychology
University of Maryland Baltimore County
Baltimore, Maryland

James Eckman, MD
Professor Emeritus, Hematology & Medical Oncology
Emory University School of Medicine
Department of Hematology and Medical Oncology
Atlanta, Georgia

Andrew Campbell, MD
Center for Cancer and Blood Disorders
Children’s National Health System
Associate Professor of Pediatrics
George Washington University School of Medicine and Health Sciences
Washington, DC

Mark Gladwin, MD
Professor and Chair
Department of Medicine
Founder, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Raffaella Colombatti, MD, PhD
Physician Azienda Ospedaliera-Università di Padova
Department of Womens’ and Child Health
Clinic of Pediatric Hematology Oncology
Via Giustiniani 3 35129
Padova Italy

Jo Howard, MB Bchir, MRCP, FRCPath
Head of Red Cell/Sickle Cell Service
Guy’s and St Thomas’ NHS Foundation Trust
London, United Kingdom

Levi Hsu, MD, PhD
Co-Chair, Co-Director, Medical and Research Advisory Committee,
Sickle Cell Disease Association of America
Vice Chief Medical Officer, Sickle Cell Disease Association of America
Director of Pediatric Sickle Cell
Professor of Pediatric Hematology-Oncology
University of Illinois at Chicago
Chicago, Illinois

Lori Crosby, PsyD
Co-Director, Innovations in Community Research,
Division of Behavioral Medicine & Clinical Psychology
Co-Director, CCTST, Community Engagement Core
Psychologist, Research, Behavioral Medicine & Clinical Psychology
Cincinnati Children’s
Professor, UC Department of Pediatrics
Cincinnati, Ohio

continued on next page
Baba Inusa  
Professor of Paediatric Haematology  
Lead Consultant Paediatric Sickle Cell and Thalassaemia  
Evelina London Children’s Hospital  
Guy’s and St Thomas’ NHS Foundation Trust  
Women and Children’s Academic Health  
Faculty of Life Sciences and Medicine  
King’s College  
London, United Kingdom

Elizabeth Klings, MD  
Associate Professor of Medicine  
Director, Center for Excellence in Sickle Cell Disease  
Director, Pulmonary Hypertension Center  
Boston University School of Medicine  
Boston, Massachusetts

Lakshmanan Krishnamurti, MD  
Professor of Pediatrics  
Director of Bone Marrow Transplant  
Joseph Kuechenmeister Aflac Field Force Chair  
Aflac Cancer and Blood Disorders Center  
Children’s Healthcare of Atlanta/Emory University  
Atlanta, Georgia

Sophie Lanzkron, MD  
Director, Sickle Cell Center for Adults  
The Johns Hopkins Hospital  
Baltimore, Maryland

Julie Makani, FRCP, PhD  
Associate Professor  
Department of Haematology and Blood Transfusion  
Muhimbili University of Health and Allied Sciences  
Dar es Salaam, Tanzania

Caterina P. Minniti, MD  
Director, Sickle Cell Center Montefiore Health System  
Professor, Departments of Medicine and Pediatrics  
Albert Einstein College of Medicine  
Bronx, New York

Genice T. Nelson, DNP, APRN, ANP-BC  
Program Director, New England Sickle Cell Institute & Connecticut Bleeding Disorders Programs, UConn Health, Farmington, Connecticut  
Board Member, Sickle Cell Disease Association of America

Isaac Odame, MB ChB, MRCP(UK), FRCPath, FRCPCH, FRCPC  
Professor, Department of Paediatrics  
University of Toronto  
The Hospital for Sick Children Division of Haematology/Oncology  
Toronto, Ontario

Kwaku Ohene-Frempong, MD  
Director Emeritus, Comprehensive Sickle Cell Center  
Emeritus Professor of Pediatrics, University of Pennsylvania  
President, Sickle Cell Foundation of Ghana  
Emeritus Board Member, Sickle Cell Disease Association of America

Gwendolyn Poles, DO  
Former Medical Director, Kline Health Center  
Faculty, Internal Medicine Program  
UPMC Pinnacle  
Harrisburg, Pennsylvania  
Board Member, Sickle Cell Disease Association of America

John D. Roberts, MD  
Yale Adult Sickle Cell Program  
Smilow Cancer Hospital at Yale New Haven  
New Haven, Connecticut

Wally Smith, MD  
Professor  
Scientific Director, VCU Center on Health Disparities  
Director, VCU Adult Sickle Cell Program  
Department of Internal Medicine Division of General Internal Medicine  
Virginia Commonwealth University  
Richmond, Virginia

Crawford J. Strunk MD  
Director, Sickle Cell Disease and Hemoglobinopathy Clinic  
Pediatric Hematology/Oncology Program  
ProMedica Ebeid Children’s Hospital  
Toledo, Ohio

Immacolata Tartaglione, MD PhD  
Department of Woman, Child and General and Specialist Surgery  
Università degli Studi della Campania “Luigi Vanvitelli”  
Naples, Italy

continued on next page
Marsha Treadwell, PhD  
Director, Sickle Cell Care Coordination Initiative  
Regional Director, Pacific Sickle Cell Regional Collaborative  
Professor of Psychiatry and Pediatrics  
University of California San Francisco Benioff Children’s Hospital Oakland  
Oakland, California

Ahmar U. Zaidi, MD  
Assistant Professor of Pediatrics  
Comprehensive Sickle Cell Center, Children’s Hospital of Michigan  
Director of Physician Network Development, University Pediatricians  
Wayne State University/Central Michigan University School of Medicine  
Detroit, Michigan

Winfred C. Wang, MD  
Emeritus, St. Jude Faculty  
Member, Department of Hematology  
St. Jude Children’s Research Hospital  
Memphis, Tennessee

Russell E. Ware, MD, PhD  
Director, Division of Hematology  
Co-Director, Cancer and Blood Diseases Institute  
Director, Global Health Center  
Marjory J. Johnson Chair of Hematology Translational Research  
Cincinnati Children’s  
Professor, UC Department of Pediatrics  
Cincinnati, Ohio

Julie Kanter Washko, MD  
Associate Professor, Division of Hematology Oncology  
Director, Adult Sickle Cell Clinic  
University of Alabama at Birmingham  
Birmingham, Alabama

Kim Smith-Whitley, MD  
Professor of Pediatrics  
Director, Comprehensive Sickle Cell Center  
Clinical Director, Division of Hematology  
The Children’s Hospital of Philadelphia  
Philadelphia, Pennsylvania  
Board Member, Sickle Cell Disease Association of America

Wanda Whitten-Shurney, MD  
CEO & Medical Director  
Sickle Cell Disease Association, Michigan Chapter Inc.  
Detroit, Michigan  
Board Member, Sickle Cell Disease Association of America